Have A Question?

Connect with Camargo today.

Contact Us
Blog & Resources Camargo Blog Regulatory

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.

October 27th, 2016

505(b)(2) Application Changes: What You Need to Know

October 18th, 2016

Extrapolation of Clinical Data for Pediatric Uses: Application for Medical Devices and Drug Products

October 13th, 2016

Effects on Combination Products: The Biologics Price Competition and Innovation Act of 2009

September 20th, 2016

Risk Evaluation and Mitigation Strategies (REMS) Basics

September 1st, 2016

Effects on Exclusivity: The Biologics Price Competition and Innovation Act of 2009

August 18th, 2016

Leveraging Postmarketing Safety Data in 505(b)(2) Drug Development Programs

August 9th, 2016

Pitfalls of Changing the Salt of a Listed Drug

August 2nd, 2016

Abuse Deterrence Labeling—Generic vs 505(b)(2) Drug Development

July 28th, 2016

The EU Regulatory Environment: National vs. Central Scientific Advice in the European Union

July 26th, 2016

Protein Product 505(b)(2)s Face a Looming Application “Dead Zone”

July 20th, 2016

Back to Basics: 505(b)(2) FAQs Part 4: Regulatory Strategies—Pharmacokinetic Studies

June 28th, 2016

The New FDA Draft Guidance on Chewables

June 21st, 2016

The GRAS is Not Always Greener

June 14th, 2016

Back to Basics: 505(b)(2) FAQs Part 3: Regulatory Strategies

June 6th, 2016

Key Inflection Point in a Drug’s Time to Market: Choice of Regulatory Pathway

May 4th, 2016

The Regulation of Follow-On Biological Products via 505(b)(2)

March 23rd, 2016

Pediatric Applicability or Not—This Revised Guidance is for You

March 21st, 2016

Is a Reference Listed Drug Mandatory in the 505(b)(2) Pathway?

January 24th, 2016

Drug Development Question? Here’s How to Communicate With the FDA!

September 13th, 2015

Enforcement Activities: FDA Removes Unapproved Prescription Ear Drops

August 25th, 2015

Examining the Amarin VASCEPA Saga

August 10th, 2015

A Review of the Regulatory History of Azelaic Acid and the Changing Requirements at FDA

July 21st, 2015

Use of Extrusion-Enabled Pharmaceutical Processes in Drug Development via a Streamlined Regulatory Pathway

July 20th, 2015

Final Rule—Drug Shortage Regulation: Incentive for Development of “Unapproved” Drugs?

Page 3 of 10

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights